Using Antiretrovirals to Prevent HIV: 
Implications of the outcome of the CAPRISA 004 
tenofovir-gel microbicide trial

SAVE THE DATE: Tuesday, 20 July 2010, 6.30pm-8.30pm
An official satellite of XVII International AIDS Conference, Vienna, Austria
Messe Wien Exhibition & Congress Center—Mini Room 10

The Global Campaign for Microbicides in partnership with CAPRISA and Treatment Action Campaign invites you to join an exciting, topical, and interactive debate on the implications of the results from CAPRISA 004, the first ARV-based candidate microbicide trial.

The results of the CAPRISA 004 trial testing tenofovir gel as a vaginal microbicide will be announced on Tuesday 20 July at 1pm at AIDS 2010, Vienna. The Tuesday evening satellite aims to further explore the results with an in-depth discussion engaging the study’s two principal investigators. Leading scientists and advocates will debate the findings and their implications on the international HIV-biomedical prevention research agenda. They will explore the potential impact of microbicides on the HIV epidemic and ask the important question: what do these results mean for women?

Meeting Chairs:
Yasmin Halima, Director, Global Campaign for Microbicides
Papa Salif Sow, Professor of Infectious Diseases, University of Dakar

Presentations:
Overview of the CAPRISA 004 results—Salim Abdool Karim, University of KwaZulu Natal
Modeling the impact of vaginal microbicides—Brian Williams, SACEMA, Stellenbosch University
Implications of CAPRISA 004 results on HIV prevention—Myron Cohen, University of North Carolina Chapel Hill

Panel Discussion 1: What do the CAPRISA 004 results mean for women?
Moderated by Yasmin Halima
Quarraisha Abdool Karim, Co-Principal Investigator of CAPRISA 004, University of KwaZulu-Natal and Columbia University
Samu Dube, Director of Africa Programmes, Global Campaign for Microbicides
Vuyiseka Dubula-Majola, General Secretary, Treatment Action Campaign
Catherine Hankins, Chief Scientific Advisor to UNAIDS

Panel Discussion 2: Scientific, research and policy implications of the CAPRISA 004 results
Moderated by Timothy Farley, Dept of Reproductive Health and Research, WHO
Carl Dieffenbach, Director, Division of AIDS, US National Institutes of Allergies and Infectious Diseases
Henry Gabelnick, Executive Director, CONRAD
Yogan Pillay, Deputy Director General, South African Department of Health
Renee Ridzon, Senior Program Officer, Bill & Melinda Gates Foundation